Distinct perturbation of the translatome by the antidiabetic drug metformin

Proceedings of the National Academy of Sciences of the United States of America

Volumn 109, Issue 23, 2012, Pages 8977-8982

  Larsson, Ola ^a   Morita, Masahiro ^b,c   Topisirovic, Ivan ^b,d   Alain, Tommy ^b,c   Blouin, Marie Jose ^d   Pollak, Michael ^b,d,e   Sonenberg, Nahum ^b,c  

^a KAROLINSKA INSTITUTE   (Sweden)

^b MCGILL UNIVERSITY   (Canada)

^c MCGILL UNIVERSITY   (Canada)

^d MCGILL UNIVERSITY   (Canada)

^e MCGILL UNIVERSITY   (Canada)

Author keywords

Polysome microarray; Posttranscriptional regulation; Translatomics

Indexed keywords

MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; METFORMIN; PP 242; RAPAMYCIN; UNCLASSIFIED DRUG;

ANTIPROLIFERATIVE ACTIVITY; ARTICLE; CELL CYCLE; CELL PROLIFERATION; CONTROLLED STUDY; GENE EXPRESSION; GENETIC ASSOCIATION; HUMAN; HUMAN CELL; PRIORITY JOURNAL; RNA TRANSLATION;

ANALYSIS OF VARIANCE; ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; CELL PROLIFERATION; HUMANS; INDOLES; METFORMIN; MICROARRAY ANALYSIS; NEOPLASMS; PROTEIN BIOSYNTHESIS; PURINES; SIROLIMUS; TOR SERINE-THREONINE KINASES;

MAMMALIA;

EID: 84861872213     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.1201689109     Document Type: Article

References (42)

1. Zoncu R, Efeyan A, Sabatini DM (2011) mTOR: From growth signal integration to cancer, diabetes and ageing. Nat Rev Mol Cell Biol 12:21-35.
2. Liu P, Cheng H, Roberts TM, Zhao JJ (2009) Targeting the phosphoinositide 3-kinase pathway in cancer. Nat Rev Drug Discov 8:627-644.
3. Guertin DA, Sabatini DM (2009) The pharmacology of mTOR inhibition. Sci Signal 2:pe24.
4. Thoreen CC, et al. (2009) An ATP-competitive mammalian target of rapamycin inhibitor reveals rapamycin-resistant functions of mTORC1. J Biol Chem 284:8023-8032.
5. Dowling RJ, et al. (2010) mTORC1-mediated cell proliferation, but not cell growth, controlled by the 4E-BPs. Science 328:1172-1176.
6. Feldman ME, et al. (2009) Active-site inhibitors of mTOR target rapamycin-resistant outputs of mTORC1 and mTORC2. PLoS Biol 7(2):e38.
7. García-Martínez JM, et al. (2009) Ku-0063794 is a specific inhibitor of the mammalian target of rapamycin (mTOR). Biochem J 421:29-42.
8. Ben Sahra I, Le Marchand-Brustel Y, Tanti JF, Bost F (2010) Metformin in cancer therapy: A new perspective for an old antidiabetic drug? Mol Cancer Ther 9:1092-1099.
9. Larsson SC, Mantzoros CS, Wolk A (2007) Diabetes mellitus and risk of breast cancer: A meta-analysis. Int J Cancer 121:856-862. (Pubitemid 47106217)
10. Larsson SC, Orsini N, Wolk A (2005) Diabetes mellitus and risk of colorectal cancer: A meta-analysis. J Natl Cancer Inst 97:1679-1687. (Pubitemid 41672234)
11. El-Mir MY, et al. (2000) Dimethylbiguanide inhibits cell respiration via an indirect effect targeted on the respiratory chain complex I. J Biol Chem 275:223-228.
12. Owen MR, Doran E, Halestrap AP (2000) Evidence that metformin exerts its anti-diabetic effects through inhibition of complex 1 of the mitochondrial respiratory chain. Biochem J 348:607-614. (Pubitemid 30410251)
13. Gwinn DM, et al. (2008) AMPK phosphorylation of raptor mediates a metabolic checkpoint. Mol Cell 30:214-226. (Pubitemid 351626684)
14. Inoki K, Zhu T, Guan KL (2003) TSC2 mediates cellular energy response to control cell growth and survival. Cell 115:577-590. (Pubitemid 37506046)
15. Dowling RJ, Zakikhani M, Fantus IG, Pollak M, Sonenberg N (2007) Metformin inhibits mammalian target of rapamycin-dependent translation initiation in breast cancer cells. Cancer Res 67:10804-10812. (Pubitemid 350145909)
16. Zakikhani M, Dowling R, Fantus IG, Sonenberg N, Pollak M (2006) Metformin is an AMP kinase-dependent growth inhibitor for breast cancer cells. Cancer Res 66:10269-10273. (Pubitemid 44799743)
17. Shaw RJ (2009) LKB1 and AMP-activated protein kinase control of mTOR signalling and growth. Acta Physiol (Oxf) 196:65-80.
18. Ben Sahra I, et al. (2011) Metformin, independent of AMPK, induces mTOR inhibition and cell-cycle arrest through REDD1. Cancer Res 71:4366-4372.
19. Kalender A, et al. (2010) Metformin, independent of AMPK, inhibits mTORC1 in a rag GTPase-dependent manner. Cell Metab 11:390-401.
20. Ma XM, Blenis J (2009) Molecular mechanisms of mTOR-mediated translational control. Nat Rev Mol Cell Biol 10:307-318.
21. Greenbaum D, Luscombe NM, Jansen R, Qian J, Gerstein M (2001) Interrelating different types of genomic data, from proteome to secretome: 'Oming in on function. Genome Res 11:1463-1468. (Pubitemid 32894671)
22. Warner JR, Knopf PM, Rich A (1963) A multiple ribosomal structure in protein synthesis. Proc Natl Acad Sci USA 49:122-129.
23. Wright GW, Simon RM (2003) A random variance model for detection of differential gene expression in small microarray experiments. Bioinformatics 19:2448-2455. (Pubitemid 38016644)
24. Larsson O, Sonenberg N, Nadon R (2011) anota: Analysis of differential translation in genome-wide studies. Bioinformatics 27:1440-1441.
25. Larsson O, Sonenberg N, Nadon R (2010) Identification of differential translation in genome wide studies. Proc Natl Acad Sci USA 107:21487-21492.
26. Geiss GK, et al. (2008) Direct multiplexed measurement of gene expression with color-coded probe pairs. Nat Biotechnol 26:317-325. (Pubitemid 351355126)
27. Anonymous; Gene Ontology Consortium (2008) The Gene Ontology project in 2008. Nucleic Acids Res 36(Database issue):D440-D444.
28. Pollak M (2008) Insulin and insulin-like growth factor signalling in neoplasia. Nat Rev Cancer 8:915-928.
29. Graff JR, Konicek BW, Carter JH, Marcusson EG (2008) Targeting the eukaryotic translation initiation factor 4E for cancer therapy. Cancer Res 68:631-634. (Pubitemid 351206735)
30. Pause A, et al. (1994) Insulin-dependent stimulation of protein synthesis by phosphorylation of a regulator of 5′-cap function. Nature 371:762-767.
31. Gingras AC, et al. (1999) Regulation of 4E-BP1 phosphorylation: A novel two-step mechanism. Genes Dev 13:1422-1437.
32. Gingras AC, et al. (2001) Hierarchical phosphorylation of the translation inhibitor 4EBP1. Genes Dev 15:2852-2864.
33. Pollak M(2010) Metformin and other biguanides in oncology: Advancing the research agenda. Cancer Prev Res (Phila) 3:1060-1065.
34. Buttgereit F, Brand MD (1995) A hierarchy of ATP-consuming processes in mammalian cells. Biochem J 312:163-167.
35. Hsieh AC, et al. (2012) The translational landscape of mTOR signalling steers cancer initiation and metastasis. Nature 485:55-61.
36. Silvera D, Formenti SC, Schneider RJ (2010) Translational control in cancer. Nat Rev Cancer 10:254-266.
37. Pollak M (2012) The insulin and insulin-like growth factor receptor family in neoplasia: An update. Nat Rev Cancer 12:159-169.
38. Baselga J, et al. (2012) Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer. N Engl J Med 366(6):520-529.
39. Petroulakis E, et al. (2009) p53-dependent translational control of senescence and transformation via 4E-BPs. Cancer Cell 16:439-446.
40. Dai M, et al. (2005) Evolving gene/transcript definitions significantly alter the interpretation of GeneChip data. Nucleic Acids Res 33(20):e175.
41. Sandberg R, Larsson O (2007) Improved precision and accuracy for microarrays using updated probe set definitions. BMC Bioinformatics 8(1):48.
42. Boyle EI, et al. (2004) GO:TermFinder - Open source software for accessing Gene Ontology information and finding significantly enriched Gene Ontology terms associated with a list of genes. Bioinformatics 20:3710-3715. (Pubitemid 40136825)